Venetoclax (VEN) and azacitidine (AZA) are used to treat patients with newly diagnosed acute myeloid leukaemia (AML) who are unfit for intensive chemotherapy and those with relapsed or refractory AML.
Understanding the real-world usage patterns and outcomes after VEN-AZA therapy failure is crucial, yet poorly studied.
